Press Releases

Home

About

Press Releases

Proaxsis

PR8

ProAxsis ProAxsis is further expanding its ProteaseTag® technology platform, via a project co-funded by the UK’s innovation agency, Innovate UK. ProAxsis has already registered a CE Mark in Europe for its ProteaseTag® Active Neutrophil Elastase Immunoassay as a biomarker of infection and inflammation in patients with chronic respiratory diseases such as bronchiectasis, COPD and cystic fibrosis. The company has now been successful with a recent application to theBioMedical Catalyst competition.

Read More
PR8

ProAxsis received an Invest NI Grant for Research and Development, supporting the company to develop new products using its innovative ProteaseTag® technology. The grant is part financed under the European Union’s Investment for Growth and Jobs Programme for Northern Ireland. The project, entitled “The development of ProteaseTags® for deubiquitinases (DUBs): innovative tools for biomarker identification and drug discovery in oncology”, will be over the next 12 months and aims to allow the design and synthesis of peptide-based inhibitors for the DUBs family, implemented followed by an assessment of their incorporation in to prototype activity-based immunoassay formats. (June 2018)

Read More
PR8

ProAxsis declared as the “Innovative Business of the Year” at the Business Eye First Trust Awards (BEFTAs) for small businesses in Northern Ireland. The awards ceremony took place May 31st in Belfast, and was compered by the UTV newsreader and Northern Ireland correspondent for ITV, Marc Mallett. Over 50 Northern Irish businesses were shortlisted across the 14 award categories. The ProAxsis team were announced as the Innovative Business of the Year by Tina McKenzie, the Chair of the Federation of Small Businesses NI, who sponsored the innovation category. (June 2018)

Read More
PR8

ProAxsis announces that two of its products, the ProteaseTag® Active NE Immunoassay, and NEATstik®, the first test to enable measurement of active neutrophil elastase at point-of-care, have been selected for inclusion in a major upcoming clinical trial. The BRIDGE study is a 3-year collaborative study, funded by the European Respiratory Society (ERS), in which1000 patients with bronchiectasis across Europe will be recruited and will have multiple assessments including microbiome,proteomics, detailed phenotyping and imaging. The study will explore novel biomarkers and demonstrate what they can add to clinical practice. (Sept 2018)

Read More

Subscribe & Follow us

Subscribe for updates & our newsletter

Curabitur vehicula tincidunt sapien velcac dolore laudantium.

Contact us for personalized support

Quick Links

Contact Info

Quick Links

Other Pages

Contact Info

Copyright © 2023 ProAxsis. All Rights Reserved

Appointment